Companies › Korro Bio
1 active drug program in 1 registered trial: 1 Phase 1; Metabolic and endocrine; next expected readout Aug 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| KRRO-121 | – | Phase 1 | Urea Cycle Disorders, Inborn | Aug 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07773246 | KRRO-121 | Phase 1 | Urea Cycle Disorders, Inborn | Metabolic and endocrine | Aug 2027 |
Cash and short-term investments of $105m on 2026-09-30; operating cash outflow about $62m a year; runway about 20 months at that burn, to Jun 2028
Press releases filed as 8-K in the last year:
Held by 5 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.